Oxidative Medicine and Cellular Longevity

Oxidative Medicine and Cellular Longevity / 2019 / Article
Special Issue

Oxidative Stress and Mitochondrial Damage in Neurodegenerative Diseases: From Molecular Mechanisms to Targeted Therapies

View this Special Issue

Research Article | Open Access

Volume 2019 |Article ID 4248529 | 29 pages | https://doi.org/10.1155/2019/4248529

Glycine Protects against Hypoxic-Ischemic Brain Injury by Regulating Mitochondria-Mediated Autophagy via the AMPK Pathway

Academic Editor: Ana Lloret
Received04 Jul 2018
Revised10 Aug 2018
Accepted14 Sep 2018
Published06 Feb 2019


Hypoxic-ischemic encephalopathy (HIE) is detrimental to newborns and is associated with high mortality and poor prognosis. Thus, the primary aim of the present study was to determine whether glycine could (1) attenuate HIE injury in rats and hypoxic stress in PC12 cells and (2) downregulate mitochondria-mediated autophagy dependent on the adenosine monophosphate- (AMP-) activated protein kinase (AMPK) pathway. Experiments conducted using an in vivo HIE animal model and in vitro hypoxic stress to PC12 cells revealed that intense autophagy associated with mitochondrial function occurred during in vivo HIE injury and in vitro hypoxic stress. However, glycine treatment effectively attenuated mitochondria-mediated autophagy. Additionally, after identifying alterations in proteins within the AMPK pathway in rats and PC12 cells following glycine treatment, cyclosporin A (CsA) and 5-aminoimidazole-4-carboxamide-1-b-4-ribofuranoside (AICAR) were administered in these models and indicated that glycine protected against HIE and CoCl2 injury by downregulating mitochondria-mediated autophagy that was dependent on the AMPK pathway. Overall, glycine attenuated hypoxic-ischemic injury in neurons via reductions in mitochondria-mediated autophagy through the AMPK pathway both in vitro and in vivo.

1. Introduction

Hypoxic-ischemic injury in the neonatal brain is associated with detrimental and lethal consequences secondary to perinatal asphyxia [1]. Neonates diagnosed with hypoxic-ischemic encephalopathy (HIE) exhibit enhanced morbidity with poor clinical outcomes, which have increased awareness of this disorder worldwide [2]. In developed countries, approximately 1–8 per 1000 live births are diagnosed with HIE, while 26 per 1000 live births suffered from this serious disease in developing countries [3]. The high cost and complicated therapeutic strategies associated with HIE typically result in difficulties maintaining adherence to treatment for patients and families. Even worse, severe cases of HIE often result in poor prognoses that include lifelong issues, like cerebral palsy, epilepsy, mental retardation, learning and cognitive disabilities, and hearing loss [4]. Thus, the development of inexpensive and effective treatment modalities is necessary to allow families to continue beneficial treatments that enhance the long-term prognoses of neonates.

It has been shown that autophagy is highly correlated with the pathogenesis of HIE, although autophagy is an important degradation process designed to protect intracellular homeostasis under conditions of hypoxic-ischemic injury [5, 6]. To a large extent, this process also degrades a significant number of abnormal proteins, injured intracellular organelles, and degraded normal proteins to influence neuronal function under conditions where fewer organelles are working [7]. In particular, the selective degradation of mitochondria is an important process in the nervous system.

Mitochondria are organelles that supply energy to the cell and play important roles in the nervous system. Suffering from the hypoxic or ischemic condition, mitochondria are sensitive and becoming swelling or mitochondrial fusion [8]. Accumulating evidence suggests that mitochondrial dysfunction also plays a central role in a variety of nervous system diseases. For example, insults of hypoxic or ischemic conditions to neurons may result from generation of reactive oxygen species (ROS), particularly reactive oxygen-free radicals or other molecules, which act as crucial physiological components of intracellular signaling pathways [9]. However, most ROS are primarily generated by damaged mitochondria [10] that typically exhibit abnormalities in mitochondrial membrane potential (MMP). In parallel, MMP acts as an indicator of mitochondria-mediated autophagy [11]. For further investigation to study mitochondria-mediated autophagy among researches, cyclosporin A (CsA), as a traditional inhibitor, is widely used to suppress this autophagy process [12].

In addition to producing the majority of intracellular adenosine triphosphate (ATP), mitochondria are also the key factor to maintain the homeostasis within the intracellular environment. The adenosine monophosphate- (AMP-) activated protein kinase (AMPK) pathway is a key sensor of mitochondrial function and is sensitive to downward trends in ATP. Under conditions of energy imbalance or ROS generation in which AMPK signaling is disrupted, ATP levels decrease and intracellular AMP levels increase with particular subunits (α, β, and γ) of AMPK to activate the AMPK pathway. α subunit of AMPK acts as a catalytic role and regulatory β and γ subunits keep the stable condition to AMPK. Among these subunits, γ subunit contains nucleotide binding domains, while β subunit should be stimulated allosterically to activate AMPK. Furthermore, α subunit is pivotal to AMPK activation, including phosphorylation [13]. In our previous concepts, the AMPK pathway always benefits recovery and plays a vital role in the cellular environment. For example, the AMPK pathway exhibits a range of activation such that it protects neurons under conditions of hypoxic attack but does not benefit neurons under hypoxic conditions if it is overactivated [14]. In parallel, phosphorylation of AMPK did not always play a protective role to maintain the energy regeneration process. It may highly conserve autophagy kinase like Atg1, which mostly stimulates mitochondria-mediated autophagy [15]. Thus, the AMPK signaling pathway reflects the condition of mitochondrial function, such as fission or the recycling of the phospholipid membranes of mitochondria [16]. Furthermore, to figure out the relation between the AMPK pathway and mitochondria-mediated autophagy, a classical agonist of the AMPK pathway, 5-aminoimidazole-4-carboxamide-1-b-4-ribofuranoside (AICAR) [17], preserves AMPK activation in vivo and in vitro, which was confirmed in the present study.

Cobalt chloride (CoCl2), as a chemical compound, is widely acknowledged as a classical stimulator to hypoxic-ischemic condition, which triggers ROS generation and transcriptional dysfunction of some genes, including hypoxia-inducible factor 1 (HIF-1) and pCNA [18]. In particular, CoCl2-induced injury may destroy mitochondrial membrane potential, ATP level, and increase mitochondrial fission [19]. PC12 cell is a cell line derived from rat pheochromocytoma and its highly differentiated cell type is similar to neuronal characteristics, which is widely used as an in vitro model for observing neuronal pathogeneses [20]. Therefore, CoCl2-treated PC12 cell, as the hypoxic model, was used in our study to observe the mitochondria insults related with autophagy.

Glycine is a common substance present in numerous biomolecules where it plays a fundamental role in cellular metabolism. Glycine also acts as a neurotransmitter or N-methyl-D-aspartate receptor coagonist, which is reported for its effectiveness among neurodegenerative diseases, like Alzheimer’s disease [21]. Moreover, mitochondria oxidatively decompose glycine into CO2, NH4+, NADH, and a methylene group to create methylenetetrahydrofolate, which sustains homeostasis [22]. However, the inhibition of oxidative phosphorylation and/or glycolytic energy production by glycine may protect intracellular energy production, which plays a protective role against neurological diseases, such as stroke or intracerebral hemorrhage [23]. Indeed, glycine protects against injuries mediated by hypoxia, hypoxia-reoxygenation, ROS, and chemical energy depletion [24]. Moreover, glycine has been increasingly employed as an effective therapeutic strategy for the protection of mitochondria in preclinical experiments in the liver [25] and kidney [26].

To date, few studies [27] have investigated whether glycine protects against hypoxic-ischemic injury in the brain by regulating mitochondria-mediated autophagy processes that are dependent on the AMPK pathway. Therefore, the present study is aimed at determining the role that glycine plays in neuroprotection via the regulation of mitochondria-mediated autophagy using both in vivo and in vitro models to aid future research.

2. Material and Methods

2.1. Drug and Reagents

Glycine (assay ≥ 98.5%; G5417-MSDS) and CoCl2·6H2O (C8661-25G) were purchased from Sigma-Aldrich (St. Louis, MO, USA). Dulbecco’s modified Eagle medium (DMEM; 10569044) and fetal bovine serum (FBS; 10099141) were obtained from Gibco (Grand Island, NY, USA). 2,3,5-Triphenyltetrazolium chloride (TTC; 17779-10X10ML-F) was purchased from Sigma-Aldrich (St. Louis, MO, USA). 2,7-dichlorodihydrofluorescein diacetate (DCFH-DA; S0033) was purchased from Beyotime (Beijing, China). 5-Aminoimidazole-4-carboxamide-1-b-4-ribofuranoside (AICAR; A9978-25MG) was acquired from Sigma-Aldrich (St. Louis, MO, USA) and cyclosporin A (CsA; S2286) was obtained from Selleckchem (Houston, TX, USA). Cell counting kit-8 (CCK-8; CK04) was gained from Solarbio (Beijing, China). MitoSOX Red (40778ES50) was delivered from Yeasen (Shanghai, China). Tetramethylrhodamine ethyl ester perchlorate (TMRE; 87917-25MG) and Hoechst 33258 (94403-1ML) were also purchased from Sigma-Aldrich (St. Louis, MO, USA). 4,6-Diamidino-2-phenylindole (DAPI; C1002) and terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL; C1088) were purchased from Beyotime (Shanghai, China).

Primary antibodies are as follows: mouse antihypoxia-inducible factor 1-alpha (HIF-1α, Abcam, Cambridge, MA, USA; H1alpha67), rabbit anti-Mitofusin 2 (Mfn-2, Cell Signaling Technology, Danvers, MA, USA; 9482s), mouse anti-parkin (Abcam, Cambridge, MA, USA; ab77924), rabbit anti-PINK1 (Abcam, Cambridge, MA, USA; ab23707), rabbit anti-p62 (Cell Signaling Technology, Danvers, MA, USA; 23214), rabbit anti-LC3 B (Cell Signaling Technology, Danvers, MA, USA; 3868), rabbit anti-Bnip3 (Abcam, Cambridge, MA, USA; ab109362), rabbit anti-Thr172 phosphorylated AMPKα (Cell Signaling Technology, Danvers, MA, USA; 50081), rabbit antiglyceraldehyde-3-phosphate dehydrogenase (GAPDH, Cell Signaling Technology, Danvers, MA, USA; 5174T), rabbit anti-AMPKα (Cell Signaling Technology, Danvers, MA, USA; 5832), and rabbit anti-Ser2448 phosphorylated mTOR (Cell Signaling Technology, Danvers, MA, USA; 5536). Secondary antibodies are as follows: goat anti-rabbit secondary antibody (ab150077) and rabbit anti-mouse secondary antibody (ab150125) were purchased from Abcam.

2.2. Animal Care, Surgery, and Ethical Certification

Sprague-Dawley (SD) rats were provided by the Animal Center of the Chinese Academy of Sciences, placed in individual housing of Wenzhou Medical University Animal Center (ethic number: wydw2014-0058), allowed free access to water and standard feed, and maintained in specific pathogen-free conditions under a 12/12 h light cycle at 23 ± 2°C and 60 ± 10% humidity. The rats were then crossbred to generate neonate SD rats that, on postnatal day 7 (P7), underwent minor surgery. Overall, 205 healthy neonatal 4-day-old rats were used in this study. 125 4-day-old rats were randomly allocated in 5 experimental groups and 25 4-day-old rats in each experimental group, and 80 7-day-old rats used to figure out the optimum dosage of glycine at a dose-dependent manner. For searching the optimum dosage of glycine, series of dose-dependent manner tests were used to figure out the most effective and economic dosage in order to gain the best recovery [28]. Briefly, 7-day-old pups in the HIE + glycine group were pretreated with an optimum intraperitoneal (i.p.) dose of glycine, while pups in the HIE + glycine + CsA and the HIE + glycine + AICAR groups were treated with CsA (5 mg/kg) [29] and AICAR (50 mg/kg) [30] started at 4-day-old rats, respectively, for 3 days, then followed by glycine administration at 7-day-old rats. The model employed in the present study was adapted from Vannucci and Vannucci [31]. For the surgery, the 7-day-old pups were anesthetized with anhydrous ether and underwent an incision at the middle of the neck followed by unilateral ligation of the left common carotid artery. Following suturing of the incision, the pups were allowed to recover for 2 h. Then, they were placed in a confined space with an environment consisting of humidified nitrogen-oxygen mixture (92% nitrogen and 8% oxygen, 3–4 l/min) for 2 h to induce further hypoxia. Pups in the sham group were anaesthetized, and the same midline incisions were performed without ligation of the common carotid arteries, followed with saline (the same volume, i.p.) pretreatment. This is aimed at guaranteeing the same surgical stimulations in both sham and experimental animals in order to exclude unrelated variables caused by surgery itself. All pups returned to their rearing cages for subsequent experimental procedures. In the following days, the rats were given daily administration of the drugs or saline. All animal procedures and operations were performed according to the animal use and care protocol based on the Guide for the Care and Use of Laboratory Animals from the National Institutes of Health and Wenzhou Medical University.

2.3. Evaluation of the Infarct Areas

To measure the infarct areas alleviated by drug administrations, 7-day-old rats from each group were anesthetized and sacrificed 24 h after surgery. 2,3,5-Triphenyltetrazolium chloride (TTC, Sigma-Aldrich, St. Louis, MO, USA) was used to quantify infarct volume and figure out the optimum dosage of glycine. Each brain was frozen at −20°C for 15 min and cut into 2 mm coronal slices. Next, the brain slices were immersed in a 1% TTC solution in the dark for 30 min at 37°C and incubated in 4% paraformaldehyde. Brain infarct areas were calculated using the ImageJ software (National Institutes of Health, Bethesda, MD, USA).

2.4. Measurement of Brain Water Content

To measure the dropsy status of injured hemispheres under hypoxic-ischemic condition and drug efficacy on the edema hemisphere, the 7-day-old rats were anesthetized with diethyl ether and sacrificed for brain analyses, as previously described [32]. The ipsilateral hemispheres from the sham group, HIE group, and HIE + glycine group were isolated to measure wet weight (accurate to 0.1 mg), and each hemisphere was placed in a drying oven (100°C) for 48 h to measure the dry weight (accurate to 0.1 mg) again. The percentages of brain water content in the hemisphere were calculated using the following equation: ([wet weight − dry weight]/wet weight) × 100%.

2.5. Histopathological Analysis

From the observation on pathological tissues, the isolated brains from each group among 7-day-old rats were collected 24 h after surgery and 14-day-old rats were gained 7 days after surgery or drug administration, perfused with phosphate-buffered saline (PBS; pH 7.4, 20 ml) followed by 4% (w/v) paraformaldehyde (20 ml). They were then embedded in paraffin and cut into coronal sections (5 μm) for histological evaluation, which showed directly about integrity of hemisphere or functional neuron quantity between the cortex and hippocampus. The paraffin-embedded brain sections were dewaxed, rehydrated, and stained with hematoxylin and eosin (HE) or Nissl solution (Solarbio, Beijing, China). The results of the histological procedures were measured using light microscopy.

2.6. Transmission Electron Microscopy

To further understand the inner autophagy process or mitochondrial status among neurons, transmission electron microscopy (TEM, H-600IV; HITACHI, Tokyo, Japan) was used to observe directly this phenomenon. The 7-day-old pups were intracardially perfused with 2.5% glutaraldehyde and 2% paraformaldehyde in cacodylate buffer (0.1 mol/l, pH 7.4), and then the brains were postfixed overnight at 4°C in the same fixative. The brains were rinsed in 1% osmium tetroxide, dehydrated in an acetone series, infiltrated in Epon 812 for a longer period, and finally embedded. Next, ultrathin sections were cut with a diamond knife and stained with uranyl acetate and lead citrate. The sections were examined using TEM and the mitochondrial forms in both the cortex and hippocampus of each group were assessed.

2.7. Hindlimb Suspension Testing

After observing pathological alterations and subcellular structures above, the further neuronal functions or improvements should also be measured. Hindlimb suspension was performed to evaluate the right hindlimb muscular strength while its ipsilateral hemisphere was damaged. Among 14-day-old rats, a hindlimb suspension test [33] was used to detect neuromuscular function in the right hindlimb. Briefly, a jar that was padded at the bottom with medical cotton balls to mitigate the consequences of falling was used and hindlimbs of the rats were placed on the edge of a tube. Behavior was scored as follows: 4, normal hindlimb separation with the tail raised; 3, hindlimbs were relatively weak and close together but not touching each other; 2, hindlimbs were often touching; 1, apparent weakness of the hindlimbs with the tail raised and limbs in a clasped position; and 0, a constant clasped condition of the hindlimbs with the tail lowered or failure to hold onto the edge for any period of time.

2.8. Berderson Behavioral Test

The Berderson behavioral test [34] was employed to assess palsy in the contralateral limbs of the 28-day-old rats. Briefly, the rats were held gently by the tail, suspended one meter above a platform, and their forelimb flexion was observed and scored as follows: 0 (normal), rats extend forelimbs toward the floor with no neurological deficits; 1, the forelimb contralateral to the injured hemisphere was often flexed in different postures including slight wrist flexion, shoulder adduction with extension at the elbow, posturing with full flexion of wrist and/or elbow, and/or adduction with severe internal rotation of the shoulder; 2, rats were placed on a large paperboard that could be gripped by the claws, gentle lateral pressure was applied behind the shoulder until the forelimbs slid several inches (which was frequently shown in each direction with their tails held), and severely dysfunctional rats exhibited consistently reduced resistance to the lateral push toward the paretic side; and 3, rats consistently circled toward the paretic side. Each neurological examination was performed in a 3–5 min period using a double-blind procedure.

2.9. Longa Assessment

After 4 weeks after model surgery, neuronal function among 28-day-old rats is ideally mature among normal adult rats. Longa scores [35] are judged at 28-day-old rats; we observed each rat walking behaviors to evaluate its ipsilateral hemisphere injury or improvement by drug administration. Scores are as follows: 0, normal function, no neurologic deficits; 1, flexion of the right front paw observed while the tail was raised, mild neurological deficit; 2, spontaneous circling to the right when walking, moderate neurological deficit; 3, body slanted to the right when walking, severe neurological deficit; and 4, not able to walk spontaneously without possible loss of consciousness. Each neurological examination was performed three times using a double-blind procedure.

2.10. Cell Cultures and Treatment

Differentiated PC12 cells were provided by the Type Culture Collection of the Chinese Academy of Sciences (Shanghai, China). The cells were cultured in DMEM (Gibco, Grand Island, NY, USA) supplemented with 10% (vol/vol) FBS (Gibco, Grand Island, NY, USA) in a humidified incubator with an atmosphere of 5% CO2 at 37°C in 6-well plates (3 ml culture media per well) or 96-well plates (200 μl culture media per well). In the CoCl2 group, the PC12 cells were only treated with CoCl2, whereas the PC12 cells in the CoCl2 + glycine group were pretreated with glycine (ps. 1 μM glycine: 1 ml culture media added with 1 μl 1 mM glycine, according to the dose-dependent manner) and then underwent hypoxic injury in the same manner as the CoCl2 group.

In another set of experiments, PC12 cells were pretreated with CsA (1 μM, Selleckchem, Houston, TX, USA) for 24 h prior to the glycine and CoCl2 treatments. To further assess the functions of the AMPK pathway using in vitro experiments, PC12 cells were pretreated with AICAR (0.5 mM) for 3 h prior to the operations mentioned above.

2.11. Cell Viability Assay

Cell viability was measured with the nonradioactive cell counting kit-8 (CCK-8, Solarbio) to understand PC12 cell conditions (activation or survival). PC12 cells at a density of 1 × 104 were seeded on a 96-well plate in DMEM supplemented with 10% (vol/vol) FBS and administered CoCl2 or glycine in a dose- and time-dependent manner after 12 h of cultivation. Next, a culture medium supplied with the CCK-8 solution was added for an additional hour and its absorbance was measured with a microplate reader (Tecan Group Ltd., Männedorf, Switzerland) at a wavelength of 490 nm.

2.12. Measurement of Intracellular ROS Production

To analyze the ROS generation under the hypoxic-ischemic environment, PC12 cells were digested with trypsin, washed twice with PBS, and finally incubated with the ROS-specific fluorescent probe dye dichlorodihydrofluorescein diacetate (DCFH-DA; Beyotime, Shanghai, China) for 30 min at 37°C. Following incubation, the cells were collected and suspended in washing buffer, and ROS production was detected using a flow cytometer.

2.13. Detection of Mitochondrial ROS

Mitochondrial ROS level was measured using MitoSOX Red (Yeasen, Shangai, China), which was a fluorescent indicator of mitochondrial superoxide anions. Briefly, PC12 cells were washed with Hank’s balanced salt solution (HBSS) and incubated in the dark with 5 μM MitoSOX Red for 20 min at 37°C. Additionally, cell nuclei were stained with 4,6-diamidino-2-phenylindol (DAPI, Beyotime) for 5 min at room temperature. The cells were washed with PBS and imaged using fluorescence microscopy (Olympus IX73) with excitation and emission filters of 510 and 580 nm, respectively.

2.14. Measurement of the MMP

The MMP was measured using confocal microscopy with tetramethylrhodamine ethyl ester (TMRE) staining (Sigma-Aldrich). This technique is aimed at discovering the function of mitochondria or indirectly reflecting the insults among mitochondria. Following administration of the study drugs as described above, the cells were treated with 50 nM TMRE and further incubated for 45 min at 37°C. Additionally, nuclei of the PC12 cells were loaded with Hoechst dye to determine the position of each cell.

2.15. Terminal Deoxynucleotidyl Transferase dUTP Nick End Labeling

Terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL; Beyotime) assays were performed following the administrations of each drug. Subsequent to TUNEL staining, the cells were stained with a DAPI solution in the dark for 5 min at room temperature to identify nuclei. This tool helped to understand the apoptosis undergoing among cellular environments. Fluorescence imaging was performed with a fluorescence microscope (Olympus IX73), and the numbers of TUNEL-positive cells are presented as the percentage of positive nuclei/total nuclei × 100%.

2.16. Immunofluorescence Analysis

For the immunofluorescence analyses, PC12 cells were washed three times with PBS and incubated with 4% paraformaldehyde at 4°C for 25 min. Next, the cells were loaded with 0.3% Triton X-100 for 15 min and incubated in 5% bovine serum albumin (BSA) at 37°C for 30 min. The primary antibody anti-Mfn-2, an indicator of further figuring out the outer membrane protein of mitochondria and indirect reflection of mitochondrial situation, was applied to the cells at 4°C for 12 h, followed by incubation with an appropriate secondary antibody at 37°C for 1 h. Additionally, the nuclei were stained with DAPI; images from each group were obtained with a fluorescence microscope (Olympus IX73) and the data were analyzed with the ImageJ software.

2.17. Monodansylcadaverine Staining

Autophagic vacuoles are frequently observed during autophagy and can be visualized by monodansylcadaverine (MDC) staining [36]. In the present study, PC12 cells were seeded in six-well plates with sterile cover slips and each group of PC12 cells was incubated with 0.05 mM MDC (Sigma-Aldrich, USA) in culture medium in the dark for 30 min at 37°C following pretreatment with a drug or an operation. After the incubation, cells were washed with PBS and analyzed with a fluorescence microscope (Olympus IX73; Olympus, Tokyo, Japan).

2.18. Western Blot Analysis

For Western blot analyses, the cells were washed with PBS, loaded with radioimmunoprecipitation assay (RIPA) buffer with the PMSF protease inhibitor, and placed upon ice for 30 min. Tissue samples from the cortex and hippocampus were isolated from the ischemic hemisphere, and proteins were extracted using a mammalian tissue extraction reagent. Additionally, the protein samples were homogenized and analyzed as previously described [37]. Briefly, equivalent amounts of protein were separated by 10% sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE), transferred to polyvinylidene difluoride (PVDF) membranes (0.22 μm), and blocked with 5% skim milk for 2 h at room temperature. Subsequently, the membranes were incubated in the appropriate primary antibodies overnight at 4°C followed by incubation with a secondary antibody (at appropriate dilutions) for 2 h at room temperature. The membranes were quantitatively analyzed using the Image Lab software with densitometry after the addition of an enhanced chemiluminescence substrate (Bio-Rad, Hercules, CA, USA).

2.19. Statistical Analysis

All data are expressed as the mean ± standard error of the mean (SEM) and were analyzed with a one-way analysis of variance (ANOVA) test followed by Newman-Keuls tests for intergroup comparisons. value less than 0.05 was considered to indicate statistical significance. value < 0.01 indicated that the probability of the experimental value falling into the control distribution was lower than a value < 0.05. value < 0.001 indicated that the probability of the experimental value falling into the control distribution was lower than a value < 0.01. All data were analyzed using the SPSS 17.0 software (SPSS Inc., Chicago, IL, USA).

3. Results

3.1. Glycine Attenuated Hypoxic-Ischemic Injury in the Brains of Neonatal Rats

In the present study, infarct volume was quantified in rats from the sham, HIE, and HIE + glycine groups. In the HIE rats, glycine reduced the infarct area at an optimum dose of 600 mg/kg (dose/body weight) (Figures 1(a) and 1(b)). Western blot analyses assessing expression of the transcription factor hypoxia-inducible factor 1-alpha (HIF-1α) revealed that several different doses of glycine (200–1000 mg/kg) significantly reduced the expression of HIF-1α, indicating a rescue effect of glycine (Figures 1(c) and 1(d)). Therefore, all further experiments were performed with 600 mg/kg of glycine as the treatment standard. The rat brains of the sham, HIE, and HIE + glycine (600 mg/kg) groups were collected and their wet and dry ratios were measured. In the paraformaldehyde-fixed brains of each group, edema was easily identified in the left hemisphere of HIE rats but glycine administration attenuated the affected area to a certain extent (Figure 1(e)). Staining procedures in the cortex and hippocampus of the HIE group revealed more obvious edema than the sham group. However, these injuries were alleviated in the HIE + glycine group. Nissl stainings of the cortex and hippocampus were analyzed to assess neuronal viability (Figures 1(c)1(k)). The number of functional neurons in Nissl-stained images was assessed to determine the effectiveness of glycine for treating or protecting neurons against hypoxic-ischemic injury. TEM images intuitively revealed the extent of mitochondrial injury in tissues. The HIE group exhibited swelling symptoms of injury in mitochondria, whereas the HIE + glycine group showed relatively normal mitochondria in neurons from the cortex and hippocampus (Figure 1(l)). Furthermore, the HIE group contained the highest quantity of autophagosomes, whereas the HIE + glycine group greatly reduced the quantity which exhibited the effectiveness of glycine upon alleviating autophagy.

3.2. Glycine Protected against Hypoxic-Ischemic Injury in the Brains via Attenuation of Mitochondrial-Mediated Autophagy

Following isolation of the cortex and hippocampus tissues, proteins were extracted for Western blot analyses. The protein levels of Binp3, p62, and microtubule-associated protein 1 light chain 3 (LC3 II/I) were assayed to determine the extent of autophagy. Additionally, Bnip3, parkin, PINK1, and Mfn2 protein levels were measured to evaluate how mitochondrial function mediated subsequent autophagy in the brain. The results indicated that protein expression in the cortex and hippocampus showed the same tendencies. The injured mitochondria exhibited dysfunction that was reflected by parkin and PINK1. Once dysfunction occurred within the mitochondria, PINK1 phosphorylated the parkin protein and both proteins accumulated on the outer membranes of mitochondria. Therefore, the expression of parkin and PINK1 was the highest among the HIE group, whereas Mfn-2 was expressed at a low level. Additionally, downstream autophagy-related proteins, such as Bnip3, parkin, PINK1, and LC3II/I, were significantly elevated in the tissues from the HIE group, whereas the HIE + glycine group showed significant improvements. Briefly, Bnip3 belongs to Bcl-2 family proteins, which acted as a sensitive factor in hypoxic condition [38] or mitochondrial dysfunction [39]. The previous study also indicated that upregulation of Bnip3 was related with the autophagy induction [40]. The level of LC3 was an important autophagic marker, which was widely used to identify autophagy proceed. p62 protein also played a role in autophagy that selectively decreased autophagy process [41]. Alteration of the protein expressions mentioned above revealed that glycine administration improved or recovered dysfunctional mitochondria and alleviated autophagy following hypoxic-ischemic injury. Following glycine treatment, parkin and PINK1 expression levels were lower than those of the HIE group and Mfn-2 protein expression began to increase. Similarly, the autophagic process was altered by glycine treatment and enhanced the recovery of mitochondria. Compared to the HIE group, p62 protein expressed at a higher degree while Bnip3 and LC3II/I protein levels were decreased a lot following glycine treatment (Figures 2(a)2(d)).

To determine whether mitochondria-mediated autophagy played a role in the regulation of pathogenesis in the nervous system, rat neonates were pretreated with CsA beginning at P4 through the HIE operation and then received daily doses of glycine only. The cortical and hippocampal samples of the HIE + glycine + CsA group revealed a protective effect of glycine. Compared to the HIE + glycine group, Mfn-2 and p62 protein levels were enhanced by glycine, whereas parkin, PINK1, Bnip3, and LC3 II/I levels were lower, which illustrated that the brains exposed to hypoxic-ischemic injury exhibited extensive mitochondria-mediated autophagy and glycine attenuated these insults by regulating this autophagy (Figures 2(e)2(h)). Moreover, histopathological analyses revealed that the cortex and hippocampus structures in the HIE + glycine + CsA group exhibited the best recovery among four groups (Figures 2(i) and 2(j)). Nissl staining procedures were conducted to determine neuron status among four groups and revealed that cortical neurons in the HIE + glycine + CsA group preserved a better functional status than in the HIE and HIE + glycine groups. In the hippocampus, neurons from CA1 and CA2–3 regions also exhibited good recovery (Figures 2(k) and 2(l)).

3.3. Glycine Eliminated Mitochondria-Mediated Autophagy via Regulation of the AMPK Pathway

Proteins in the AMPK pathway, including p-AMPKα and p-mammalian target of rapamycin (p-mTOR), were also assessed and showed differences among groups in the cortex or hippocampus. p-AMPKα proteins were expressed at the highest level in the HIE group while p-mTOR expression decreased greatly. In the HIE + glycine group, glycine treatment alleviated the increase in p-AMPKα protein expression and improved p-mTOR expression, which confirmed that glycine administration influenced the AMPK pathway in vivo (Figures 3(a) and 3(b)).

To examine the relationships among HIE pathogenesis, glycine, and the AMPK pathway, an agonist of the AMPK pathway, AICAR, was employed to overactivate the AMPK pathway in rats under HIE operations. In the HIE + glycine + AICAR group, p-AMPKα protein expression increased, whereas p-mTOR protein expressions and other proteins associated with mitochondria-mediated autophagy exhibited poorer results than the HIE + glycine group. At the same time, parkin, PINK1, Bnip3, and LC3 II/I protein levels showed the highest degree, whereas Mfn-2 and p62 protein expressed the lowest level among four groups (Figures 3(c)3(f)). Taken together, these results indicate that overactivation of AMPK blocked the effectiveness of glycine that downregulates the AMPK pathway and subsequently influences AMPK-regulated autophagy. In other words, compared with the HIE group, glycine administration could downregulate the AMPK pathway in the hypoxic-ischemic insult and alleviate mitochondria-mediated autophagy to gain the protection in the HIE + glycine group.

3.4. Glycine Improved Prognosis of Rats following Hypoxic-Ischemic Injury

The bodyweights of the pups were assessed at three different ages: 7, 14, and 28 days. The bodyweights did not differ significantly in each group at 7 days (before operations). However, at 14 days, the HIE + glycine group showed improvements in bodyweight, compared with the HIE and HIE + glycine + AICAR groups. The HIE + glycine + CsA group exhibited the best weight gain among five groups, whereas rats from the HIE + glycine + AICAR group showed the lowest amount of weight gain. At 28 days, the rats of the HIE + glycine + AICAR group exhibited the lowest weight and two pups died. Following long-term glycine treatment, there was no significant difference between the HIE + glycine group and the HIE + glycine + CsA group, though these two groups exhibited better weight gains than the HIE group (Figure 4(a)).

At 7 days after surgery, three neonate rats from each group were sacrificed to further investigate the protective effects of glycine. Atrophy in the left brain showed significant improvements following treatment with glycine or glycine combined with CsA (Figure 4(b)). The HIE + glycine + AICAR group exhibited serious atrophy and had the worst prognosis among five groups. HE staining revealed the efficacy of glycine, especially in the HIE + glycine + AICAR group, in that the cortex and hippocampus exhibited considerable atrophy and were difficult to recognize. However, brain tissues from the HIE + glycine group and the HIE + glycine + CsA group exhibited better recovery than the HIE and HIE + glycine + ICAR groups (Figure 4(c)).

The present study also assessed neuromuscular ability in 14-day-old pups after surgery (Table 1). Over a period of 28 days, Longa and Berderson tests (Tables 2 and 3, respectively) were performed to measure neurodeficiencies in neuromuscular behaviors. The HIE + glycine + CsA group had the best scores on the behavioral test, whereas the condition of the HIE + glycine + AICAR group did not differ significantly from the HIE group (Table 1). At 28 days of age, the Longa test revealed that the HIE + glycine and HIE + glycine + CsA groups showed better mobility compared with the HIE and HIE + glycine + AICAR groups. Additionally, based on the results above, it was evident that the HIE + glycine + AICAR group did not perform well on the Longa test (Table 2). In parallel, the rats from this group also did not perform well on the Berderson test (Table 3).

GroupNumberHindlimb suspension

Sham114.00 ± 0.00
HIE111.24 ± 0.11
HIE + glycine112.15 ± 0.12,###
HIE + glycine + CsA112.60 ± 0.11,###,&&
HIE + glycine + AICAR111.30 ± 0.11,&&&

Dates were presented as mean ± SEM from rats from each group. versus the sham group. ### versus the HIE group. && and &&& versus the HIE + glycine group.

GroupNumberHindlimb suspension

Sham80.00 ± 0.00
HIE81.75 ± 0.14
HIE + glycine81.00 ± 0.13,###
HIE + glycine + CsA80.83 ± 0.13,###
HIE + glycine + AICAR61.70 ± 0.13,&&&

Dates were presented as mean ± SEM from rats from each group. versus the sham group. ### versus the HIE group. &&& versus the HIE + glycine group.

GroupNumberHindlimb suspension

Sham80.00 ± 0.00
HIE82.08 ± 0.15
HIE + glycine81.45 ± 0.10,###
HIE + glycine + CsA80.95 ± 0.11,###,&&
HIE + glycine + AICAR62.04 ± 0.14,&&&

Dates were presented as mean ± SEM from rats from each group. versus the sham group. ### versus the HIE group. && and &&& versus the HIE + glycine group.
3.5. Glycine Attenuated CoCl2-Induced Cytotoxicity, Cellular ROS, and Apoptosis in PC12 Cells

The initial effects of CoCl2 on neurons were detected using the CCK8 method. In the present study, CoCl2 (800–1000 μM) significantly inhibited cellular viability within 24 h in a dose- and time-dependent manner compared with the control group (Figure 5(a)). Moreover, the optimum dose of glycine (8–10 μM) effectively protected PC12 cells against CoCl2-induced injury (800–1000 μM) in the same manner as the CoCl2 group (Figure 5(b)). DCFH-DA fluorescence was used to detect the level of ROS generation in each group and revealed that glycine pretreatment decreased ROS generation and protected against CoCl2-induced injury in PC12 cells (Figure 5(c)). TUNEL staining indicated that glycine also downregulated apoptosis to protect PC12 cells (Figure 5(d)).

3.6. Glycine Attenuated CoCl2-Induced Mitochondrial ROS Generation, Restored the MPP, Improved Mfn-2 Protein Levels, and Alleviated Autophagy in PC12 Cells

As an indication of injured status in cells, mitochondria largely generated superoxide molecules by influencing various signaling pathways. MitoSOX, which confirmed the position of the mitochondrial matrix and detected superoxide anions in mitochondria, was used to assess oxidative stress in mitochondria of PC12 cells. Cells that underwent CoCl2 injury showed a significant increase in oxidative stress in mitochondria (Figure 6(a)), but the administration of an optimum dose of glycine lowered ROS generation. Additionally, PC12 cells were loaded with TMRE to evaluate the MMP, which reflected mitochondrial function. CoCl2 impaired mitochondria by decreasing the MMP, but glycine dramatically promoted the MMP (Figure 6(b)). Furthermore, Mfn-2 expression was at a low level in the CoCl2 group (Figure 6(c)), but glycine upregulated the Mfn-2 protein expression. According to the results of MDC staining, which specifically identified autophagic vacuoles, showed that the CoCl2 + glycine group gained the lower value of MDC immunofluorescence than the CoCl2 group. This result also illustrated that glycine could downregulate autophagy (Figure 6(d)).

3.7. Glycine Protected PC12 Cells against CoCl2-Induced Injury via Regulation of Mitochondria-Mediated Autophagy

The present study examined the expression of parkin, PINK1, Mfn-2, Bnip3, p62, and LC3II/I (Figures 7(a) and 7(b)) and found increased expression of parkin, PINK1, Bnip3, and LC3II/I in the CoCl2 group. However, glycine pretreatment before CoCl2 (CoCl2 + glycine) significantly reduced such effect. At the same time, the expressions of Mfn-2 and p62 decreased following CoCl2 injury, but glycine pretreatment promoted the expressions of Mfn-2 and p62. CsA, a conventional inhibitor of mitochondria-mediated autophagy, was used to determine whether glycine regulated autophagy. Following treatment with a combination of CsA and glycine, the expressions of parkin, PINK1, Bnip3, and LC3 II/I were largely inhibited, whereas the expression of Mfn-2 and p62 was increased (Figures 7(c) and 7(d)). Additionally, the administration of CsA increased cellular viability such that it was better compared with the CoCl2 + glycine group (Figure 7(e)).

MDC staining revealed that the CoCl2 + glycine + CsA and CoCl2 + glycine groups exhibited a less degree of autophagy, particularly the CoCl2 + glycine + CsA group (Figure 7(f)). TUNEL staining in PC12 cells further confirmed that glycine protected PC12 cells (Figure 7(g)). Assessments of mitochondrial function included measurements of mitochondrial ROS generation, MMP, and Mfn-2 expression (Figures 7(h)7(j)). In all four groups, glycine significantly decreased mitochondria-mediated autophagy, especially via the parkin/ PINK1 pathway, which has been linked to mitochondria-mediated autophagy.

3.8. Glycine Protected PC12 Cells against CoCl2 Injury via Regulation of AMPK-Dependent Mitochondria-Mediated Autophagy

Because AMPK is phosphorylated upon activation of the AMPK pathway, it acts an energy sensor that reflects the condition of mitochondria. Analyses of p-AMPK expression in PC12 cells revealed high levels of p-AMPKα in the CoCl2-treated group, but glycine pretreatment reduced the levels of p-AMPKα. The mTOR pathway is the downstream of the AMPK pathway, and assessments in the present study showed that CoCl2 injury had an adverse effect on this pathway as well (Figures 8(a) and 8(b)). To determine whether the AMPK pathway modulated CoCl2-induced mitochondria-mediated autophagy, AICAR, an AMPK pathway agonist was used to modulate protein expression. In the CoCl2 + glycine + AICAR group, the expressions of parkin, PINK1, Bnip3, LC3II/I, and p-AMPKα were evident at a high degree while the expressions of Mfn-2, p-mTOR, and p62 were low (Figures 8(c) and 8(d)). At the same time, the group administrated CsA in combination with glycine exhibited the lowest viability (Figure 8(e)).

MDC staining revealed that the CoCl2 + glycine + AICAR group had the highest intensity of autophagy of the four groups, whereas the CoCl2 + glycine group exhibited attenuations in autophagy (Figure 8(f)). Moreover, TUNEL staining revealed that glycine pretreatment protected against CoCl2 injury, whereas overactivation of the AMPK pathway in the CoCl2 + glycine + AICAR group produced the highest number of TUNEL-positive cells (Figure 8(g)). Immunofluorescence analyses of the PC12 cells revealed that the mitochondrial function of the CoCl2 + glycine + AICAR group did not show significant improvements with the CoCl2 group (Figures 8(h)8(j)). However, the CoCl2 + glycine group exhibited high levels of protection against CoCl2 injury. Parallel analyses confirmed the overactivation of the AMPK pathway by AICAR. This result suggests that the AMPK pathway played an important role in CoCl2-induced mitochondria-mediated autophagy.

4. Discussion

The present study was the first to investigate whether glycine could protect against hypoxic-ischemic injury in the nervous system by regulating mitochondria-mediated autophagy via the AMPK pathway using in vivo and in vitro experiments.

Pathogeneses of HIE have been studied a lot, such as endoplasmic reticulum stress [42], inflammation among white matter [43], or neuron apoptosis [44]. In recent years, autophagy has become the new target in various systems. Without exception, a few researches illustrated the relation between HIE and autophagy. Previous studies have demonstrated that autophagy is related to a wide variety of physiological and pathological processes [45, 46]. Particularly in hypoxic-ischemic situations, autophagy plays a vital role in the metabolic regulation of different organs [4749]. Furthermore, autophagy represents a significant mechanism by which cellular homeostasis is maintained to allow for further adjustments in HIE [50, 51]. Compared with some results about autophagy, their opinions about appropriately increasing profitable autophagy gained the protection in HIE. It is true that autophagy gains two extremes, protection and destruction [52]. An excessive degree of autophagy can be harmful to the whole cell or tissues [53, 54], which was demonstrated in the present study. Our results demonstrated that the injured side of the brain was severely hydrophobic, exhibited signs of cortical liquidation, and showed destruction of the cortex and hippocampus following HIE operations. Additionally, there was a high level of LC3 protein expression, which is a traditional indicator of autophagy in the HIE and CoCl2 groups. Bnip3, which can be used to measure autophagy, was also expressed at a high level in the HIE and CoCl2 groups. This is similar to the findings of previous studies showing that Bnip3 is sensitive to hypoxic-ischemic pathogenesis and may potentially serve as a biomarker of excessive autophagy, which has been verified in other studies [55]. CsA, a conventional inhibitor of mitochondria-mediated autophagy, largely decreased the intensity of autophagy compared with the CoCl2 + glycine and HIE + glycine groups. In the in vivo experiments, neonatal rats were pretreated with CsA to inhibit autophagy and brain samples from these animals showed good recovery when CsA was combined with daily glycine administration. Similar results were obtained from the in vitro experiments that revealed good cell viability and MMP. Taken together, the present findings indicate that high levels of mitochondria-mediated autophagy degraded abnormal proteins and digested organelles, particularly mitochondria but influenced normal functioning proteins and organelles, which could be catastrophic to the cellular environment and body. The present TEM results easily identified edematous mitochondria in all three groups of rats. Outer membrane protein levels were also assessed to determine mitochondrial function. The expression levels of Mfn-2 are indicative of the dysfunction or fusion of mitochondria, which, in turn, activates autophagy [56, 57]. Moreover, PINK1 phosphorylates parkin and recruits it to the mitochondria, which damage these organelles. In the HIE group and CoCl2 group, the high expression levels of parkin and PINK1 indicated serious damage to the mitochondria. However, MDC staining in PC12 cells revealed that glycine treatment effectively alleviated the autophagy process compared with the CoCl2 and CoCl2 + glycine + AICAR groups. Therefore, novel treatments that immediately downregulate mitochondria-mediated autophagy are urgently needed to aid adjustment and recovery.

The administration of glycine is an effective treatment following hypoxic or hypoxic-ischemic injury in the liver [58], kidney [26], and various cell types [5961]. In the present study, there were significant decreases in LC3 and Bnip3 protein levels following glycine pretreatment. At the same time, electron microscopy analyses indicated that glycine inhibited excessive autophagy. It is known that glycine protects against energy depletion by promoting the metabolism of intracellular or mitochondrial functions [24]. In the present study, glycine attenuated hypoxic-ischemic injury in the brain and improved mitochondrial function. HE and Nissl staining procedures revealed that glycine decreased the number of dying neurons and ameliorated the expression of related proteins while immunofluorescent analyses showed that outer membrane proteins in the mitochondria were altered by glycine. Taken together, these findings indicated that glycine could be an effective strategy for the promotion of mitochondrial function. Furthermore, glycine downregulated proteins related to mitochondria-mediated autophagy. Moreover, seven consecutive days of treatment with glycine resulted in a good prognosis in the behavioral test in 28-day-old rats. However, it has also been shown that glycine regulates the basic states of function in astrocytes and microglia by activating glycine receptors to promote recovery in the nervous system [62]. The present study did not verify the effectiveness of glycine in nonneuronal cell types.

AMPK is an energy-sensing center activated by stress or dysfunction in mitochondria [16, 63]. ATP deficiencies, or an increased ratio of AMP to ATP, usually originate from dysfunction of mitochondria. Under the hypoxic-ischemic insult, the mitochondria are sensitive (observing mitochondrial status), generating ROS and making chaos in energy supply. Subsequently, activation of the AMPK pathway (activated by α subunit in the ATP/AMP disorder) modulates mitochondrial function under conditions of stress, hypoxia, and/or ischemia [64]. In this process, extensive phosphorylation of AMPK also maintains autophagy kinase, which mostly induces mitochondria-mediated autophagy. Analyzing autophagy protein expressions among animal and cell models, we will help to directly understand the condition of mitochondria-mediated autophagy in vivo and in vitro.

Previous studies have demonstrated that mTOR protein expression is inhibited by activation of AMPK and that mTORC2 [65], as part of mTOR, plays a role to participate in the autophagy process [66]. Under hypoxic attack and other unfavorable conditions, AMPK activation inhibits the mTOR signaling pathway. In the present study, there were high levels of phosphorylation of AMPK expressed but low levels of p-mTOR following the HIE group or CoCl2 injury.

One previous study reported that the suppression of AMPK activity had no harmful effects on the basic functions of mitochondria and good recovery of cellular metabolism was evident on following treatment [67]. However, the role of the AMPK pathway is complex and may vary under conditions. Within a specific range, AMPK plays a protective role; however, overactivation of the AMPK pathway can worsen intracellular status, especially in neurons exposed to a hypoxic environment [14]. To further understand the relationship of glycine with the AMPK pathway, AICAR, an agonist of AMPK, was administrated to measure autophagic proteins. Glycine treatment inhibited AICAR-induced activation of the AMPK pathway and downregulated autophagy. Of the three groups in the present study, p-AMPK expression levels were highest following HIE or CoCl2 injury. However, the administration of AICAR in combination with glycine demonstrated the activation of AMPK proteins, ROS degeneration, and worsened mitochondrial function, which then enhanced autophagy. Detailed molecular mechanisms underlying inactivation of the AMPK pathway by glycine still require further investigation. However, previous studies have suggested several possibilities [68]. For example, fatty acid oxidation increases and glucose oxidation suppressed following AMPK activation [69, 70]. However, glycine pretreatment may attenuate fatty acid oxidation and adjust glucose oxidation to normal levels, which would aid in recovery of the whole neuron and its functions. AICAR, as an agonist of the AMPK pathway, revealed that activation of the AMPK pathway had detrimental effects. Rats that received daily treatments of AICAR and glycine did not show good recovery in terms of protection or further treatment. Similarly, PC12 cells pretreated with AICAR and glycine exhibited poor recovery following overactivation of the AMPK pathway.

There are several limitations of the present study that should be noted when interpreting the results. HIE models typically use knockout rats to assess the manner in which glycine ameliorates HIE injury. Moreover, primary neurons can be collected and analyzed to assess the effects of glycine but evaluation of various cell types would strengthen the present results. Finally, it remains to be elucidated whether glycine regulates fatty acid oxidation.

In summary, the present data provide the first evidence that glycine attenuated hypoxic-ischemic injury in neurons or the nervous system by decreasing mitochondria-mediated autophagy through regulating the AMPK pathway using both in vitro and in vivo experiments. Since the pathogeneses of HIE are currently too complex to develop accurate and effective therapy, glycine may serve as a more inexpensive and effective alternative to other medicines. Additionally, identifying the optimum dosage of glycine for improved prognosis will be important.

Data Availability

The data used to support the findings of this study are available from the corresponding author upon request.

Conflicts of Interest

The authors declare that they have no conflict of interest.

Authors’ Contributions

Cai CC drafted the article and designed the study mainly. Zhu JH helped to design experiments and write part of the article. Ye LX and Dai YY helped to design figures and contribute to analyze part of the data. Fang MC, Hu YY, and Pan SL contributed to design figures and helped to analyze related data. Chen S, Li PJ, and Fu XQ designed tables and helped to analyze related data. Lin ZL contributed to critical revision of the manuscript. They approved the final version and agreed to be accountable for the study.


This study was funded by the National Natural Science Foundation of China (grant numbers 81701489 and 81771624), the Beijing Medical and Health Foundation (grant number B17137), and the Wenzhou Science and Technology Bureau (grant number Y20160020).

Supplementary Materials

Supplementary Figure 1. The dosage of glycine pretreatment has no effect on normal cortex status of neonatal rats. (A) Protein expressions were examined for evaluating mitochondria-mediated autophagy extent between the sham and sham + glycine groups. (B) Analyses of all protein expressions. . Supplementary Figure 2. The dosage of glycine pretreatment has no effect on normal hippocampus status of neonatal rats. (A) Protein expressions were examined for evaluating mitochondria-mediated autophagy extent between the sham and sham + glycine groups. (B) Analyses of all protein expressions. . Supplementary Figure 3. The dosage of glycine administration has no influence on normal status of PC12 cells. (A) Protein expressions were examined for evaluating mitochondria-mediated autophagy extent between control and control + glycine groups. (B) Analyses of all protein expressions. . (C) Cell viability between two groups. . (Supplementary Materials)


  1. L. Lehtonen, A. Gimeno, A. Parra-Llorca, and M. Vento, “Early neonatal death: a challenge worldwide,” Seminars in Fetal & Neonatal Medicine, vol. 22, no. 3, pp. 153–160, 2017. View at: Publisher Site | Google Scholar
  2. Á. Sánchez-Illana, A. Núñez-Ramiro, M. Cernada et al., “Evolution of energy related metabolites in plasma from newborns with hypoxic-ischemic encephalopathy during hypothermia treatment,” Scientific Reports, vol. 7, no. 1, article 17039, 2017. View at: Publisher Site | Google Scholar
  3. M. Douglas-Escobar and M. D. Weiss, “Hypoxic-ischemic encephalopathy: a review for the clinician,” JAMA Pediatrics, vol. 169, no. 4, pp. 397–403, 2015. View at: Publisher Site | Google Scholar
  4. A. J. du Plessis and J. J. Volpe, “Perinatal brain injury in the preterm and term newborn,” Current Opinion in Neurology, vol. 15, no. 2, pp. 151–157, 2002. View at: Publisher Site | Google Scholar
  5. Q. Lu, V. A. Harris, S. Kumar, H. M. Mansour, and S. M. Black, “Autophagy in neonatal hypoxia ischemic brain is associated with oxidative stress,” Redox Biology, vol. 6, pp. 516–523, 2015. View at: Publisher Site | Google Scholar
  6. S. Carloni, M. C. Albertini, L. Galluzzi, G. Buonocore, F. Proietti, and W. Balduini, “Increased autophagy reduces endoplasmic reticulum stress after neonatal hypoxia-ischemia: role of protein synthesis and autophagic pathways,” Experimental Neurology, vol. 255, pp. 103–112, 2014. View at: Publisher Site | Google Scholar
  7. N. Mizushima, B. Levine, A. M. Cuervo, and D. J. Klionsky, “Autophagy fights disease through cellular self-digestion,” Nature, vol. 451, no. 7182, pp. 1069–1075, 2008. View at: Publisher Site | Google Scholar
  8. Q. Han, G. Li, M. S. M. Ip et al., “Haemin attenuates intermittent hypoxia-induced cardiac injury via inhibiting mitochondrial fission,” Journal of Cellular and Molecular Medicine, vol. 22, no. 5, pp. 2717–2726, 2018. View at: Publisher Site | Google Scholar
  9. J. Gao, Y. Deng, C. Yin et al., “Icariside II, a novel phosphodiesterase 5 inhibitor, protects against H2O2-induced PC12 cells death by inhibiting mitochondria-mediated autophagy,” Journal of Cellular and Molecular Medicine, vol. 21, no. 2, pp. 375–386, 2017. View at: Publisher Site | Google Scholar
  10. J. Huang, G. Y. Lam, and J. H. Brumell, “Autophagy signaling through reactive oxygen species,” Antioxidants & Redox Signaling, vol. 14, no. 11, pp. 2215–2231, 2011. View at: Publisher Site | Google Scholar
  11. S. Rodriguez-Enriquez, L. He, and J. J. Lemasters, “Role of mitochondrial permeability transition pores in mitochondrial autophagy,” The International Journal of Biochemistry & Cell Biology, vol. 36, no. 12, pp. 2463–2472, 2004. View at: Publisher Site | Google Scholar
  12. C. Zhang, X. Yu, J. Gao et al., “PINK1/parkin-mediated mitophagy was activated against 1,4-benzoquinone-induced apoptosis in HL-60 cells,” Toxicology in Vitro, vol. 50, pp. 217–224, 2018. View at: Publisher Site | Google Scholar
  13. A. S. Kim, E. J. Miller, T. M. Wright et al., “A small molecule AMPK activator protects the heart against ischemia-reperfusion injury,” Journal of Molecular and Cellular Cardiology, vol. 51, no. 1, pp. 24–32, 2011. View at: Publisher Site | Google Scholar
  14. X. Zhang, R. Gao, J. Li et al., “A pharmacological activator of AMP-activated protein kinase protects hypoxic neurons in a concentration-dependent manner,” Neurochemical Research, vol. 35, no. 8, pp. 1281–1289, 2010. View at: Publisher Site | Google Scholar
  15. J. Kim, M. Kundu, B. Viollet, and K. L. Guan, “AMPK and mTOR regulate autophagy through direct phosphorylation of Ulk1,” Nature Cell Biology, vol. 13, no. 2, pp. 132–141, 2011. View at: Publisher Site | Google Scholar
  16. E. Q. Toyama, S. Herzig, J. Courchet et al., “AMP-activated protein kinase mediates mitochondrial fission in response to energy stress,” Science, vol. 351, no. 6270, pp. 275–281, 2016. View at: Publisher Site | Google Scholar
  17. C. Cerveró, N. Montull, O. Tarabal, L. Piedrafita, J. E. Esquerda, and J. Calderó, “Chronic treatment with the AMPK agonist AICAR prevents skeletal muscle pathology but fails to improve clinical outcome in a mouse model of severe spinal muscular atrophy,” Neurotherapeutics, vol. 13, no. 1, pp. 198–216, 2016. View at: Publisher Site | Google Scholar
  18. G. Wang, T. K. Hazra, S. Mitra, H. M. Lee, and E. W. Englander, “Mitochondrial DNA damage and a hypoxic response are induced by CoCl(2) in rat neuronal PC12 cells,” Nucleic Acids Research, vol. 28, no. 10, pp. 2135–2140, 2000. View at: Publisher Site | Google Scholar
  19. Y. He, X. Gan, L. Zhang et al., “CoCl2 induces apoptosis via a ROS-dependent pathway and Drp1-mediated mitochondria fission in periodontal ligament stem cells,” American Journal of Physiology-Cell Physiology, vol. 315, no. 3, pp. C389–C397, 2018. View at: Publisher Site | Google Scholar
  20. J. A. Roth, L. Feng, J. Walowitz, and R. W. Browne, “Manganese-induced rat pheochromocytoma (PC12) cell death is independent of caspase activation,” Journal of Neuroscience Research, vol. 61, no. 2, pp. 162–171, 2000. View at: Publisher Site | Google Scholar
  21. V. Moschetti, M. Desch, S. Goetz et al., “Safety, tolerability and pharmacokinetics of oral BI 425809, a glycine transporter 1 inhibitor, in healthy male volunteers: a partially randomised, single-blind, placebo-controlled, first-in-human study,” European Journal of Drug Metabolism and Pharmacokinetics, vol. 43, no. 2, pp. 239–249, 2018. View at: Publisher Site | Google Scholar
  22. A. S. Tibbetts and D. R. Appling, “Compartmentalization of mammalian folate-mediated one-carbon metabolism,” Annual Review of Nutrition, vol. 30, no. 1, pp. 57–81, 2010. View at: Publisher Site | Google Scholar
  23. D. Zhao, J. Chen, Y. Zhang et al., “Glycine confers neuroprotection through PTEN/AKT signal pathway in experimental intracerebral hemorrhage,” Biochemical and Biophysical Research Communications, vol. 501, no. 1, pp. 85–91, 2018. View at: Publisher Site | Google Scholar
  24. F. Petrat, K. Boengler, R. Schulz, and H. de Groot, “Glycine, a simple physiological compound protecting by yet puzzling mechanism(s) against ischaemia-reperfusion injury: current knowledge,” British Journal of Pharmacology, vol. 165, no. 7, pp. 2059–2072, 2012. View at: Publisher Site | Google Scholar
  25. R. Heidari, V. Ghanbarinejad, H. Mohammadi et al., “Mitochondria protection as a mechanism underlying the hepatoprotective effects of glycine in cholestatic mice,” Biomedicine & Pharmacotherapy, vol. 97, pp. 1086–1095, 2018. View at: Publisher Site | Google Scholar
  26. L. Jiang, X. Qin, X. Zhong et al., “Glycine-induced cytoprotection is mediated by ERK1/2 and AKT in renal cells with ATP depletion,” European Journal of Cell Biology, vol. 90, no. 4, pp. 333–341, 2011. View at: Publisher Site | Google Scholar
  27. A. Roldan, J. Figueras-Aloy, R. Deulofeu, and R. Jimenez, “Glycine and other neurotransmitter amino acids in cerebrospinal fluid in perinatal asphyxia and neonatal hypoxic-ischaemic encephalopathy,” Acta Paediatrica, vol. 88, no. 10, pp. 1137–1141, 1999. View at: Publisher Site | Google Scholar
  28. H. Mori, K. Momosaki, J. Kido et al., “Amelioration by glycine of brain damage in neonatal rat brain following hypoxia-ischemia,” Pediatrics International, vol. 59, no. 3, pp. 321–327, 2017. View at: Publisher Site | Google Scholar
  29. S.-g. Qiao, Y. Sun, B. Sun et al., “Sevoflurane postconditioning protects against myocardial ischemia/reperfusion injury by restoring autophagic flux via an NO-dependent mechanism,” Acta Pharmacologica Sinica, pp. 1–11, 2018. View at: Publisher Site | Google Scholar
  30. M. Dulovic, M. Jovanovic, M. Xilouri et al., “The protective role of AMP-activated protein kinase in alpha-synuclein neurotoxicity in vitro,” Neurobiology of Disease, vol. 63, pp. 1–11, 2014. View at: Publisher Site | Google Scholar
  31. R. C. Vannucci and S. J. Vannucci, “Perinatal hypoxic-ischemic brain damage: evolution of an animal model,” Developmental Neuroscience, vol. 27, no. 2–4, pp. 81–86, 2005. View at: Publisher Site | Google Scholar
  32. W. Zhang, H. Zhang, H. Mu et al., “Omega-3 polyunsaturated fatty acids mitigate blood-brain barrier disruption after hypoxic-ischemic brain injury,” Neurobiology of Disease, vol. 91, pp. 37–46, 2016. View at: Publisher Site | Google Scholar
  33. D. N. Feather-Schussler and T. S. Ferguson, “A battery of motor tests in a neonatal mouse model of cerebral palsy,” Journal of Visualized Experiments, no. 117, 2016. View at: Publisher Site | Google Scholar
  34. Y. Yang, X. J. Zhang, J. Yin, and L. T. Li, “Brain damage related to hemorrhagic transformation following cerebral ischemia and the role of KATP channels,” Brain Research, vol. 1241, pp. 168–175, 2008. View at: Publisher Site | Google Scholar
  35. S. Liang, Y. Lin, B. Lin et al., “Resting-state functional magnetic resonance imaging analysis of brain functional activity in rats with ischemic stroke treated by electro-acupuncture,” Journal of Stroke and Cerebrovascular Diseases, vol. 26, no. 9, pp. 1953–1959, 2017. View at: Publisher Site | Google Scholar
  36. S. J. Cho, S. M. Yun, C. Jo et al., “SUMO1 promotes Aβ production via the modulation of autophagy,” Autophagy, vol. 11, no. 1, pp. 100–112, 2015. View at: Publisher Site | Google Scholar
  37. T. Mahmood and P. C. Yang, “Western blot: technique, theory, and trouble shooting,” North American Journal of Medical Sciences, vol. 4, no. 9, pp. 429–434, 2012. View at: Publisher Site | Google Scholar
  38. L. A. Kubasiak, O. M. Hernandez, N. H. Bishopric, and K. A. Webster, “Hypoxia and acidosis activate cardiac myocyte death through the Bcl-2 family protein BNIP3,” Proceedings of the National Academy of Sciences of the United States of America, vol. 99, no. 20, pp. 12825–12830, 2002. View at: Publisher Site | Google Scholar
  39. K. M. Regula, K. Ens, and L. A. Kirshenbaum, “Inducible expression of BNIP3 provokes mitochondrial defects and hypoxia-mediated cell death of ventricular myocytes,” Circulation Research, vol. 91, no. 3, pp. 226–231, 2002. View at: Publisher Site | Google Scholar
  40. S. Daido, T. Kanzawa, A. Yamamoto, H. Takeuchi, Y. Kondo, and S. Kondo, “Pivotal role of the cell death factor BNIP3 in ceramide-induced autophagic cell death in malignant glioma cells,” Cancer Research, vol. 64, no. 12, pp. 4286–4293, 2004. View at: Publisher Site | Google Scholar
  41. A. Bresciani, M. C. Spiezia, R. Boggio et al., “Quantifying autophagy using novel LC3B and p62 TR-FRET assays,” PLoS One, vol. 13, no. 3, article e0194423, 2018. View at: Publisher Site | Google Scholar
  42. S. Liu, D. Xin, L. Wang et al., “Therapeutic effects of L-cysteine in newborn mice subjected to hypoxia-ischemia brain injury via the CBS/H2S system: role of oxidative stress and endoplasmic reticulum stress,” Redox Biology, vol. 13, pp. 528–540, 2017. View at: Publisher Site | Google Scholar
  43. L. R. Shiow, G. Favrais, L. Schirmer et al., “Reactive astrocyte COX2-PGE2 production inhibits oligodendrocyte maturation in neonatal white matter injury,” Glia, vol. 65, no. 12, pp. 2024–2037, 2017. View at: Publisher Site | Google Scholar
  44. X. H. Ge, L. Shao, and G. J. Zhu, “Oxymatrine attenuates brain hypoxic-ischemic injury from apoptosis and oxidative stress: role of p-Akt/GSK3β/HO-1/Nrf-2 signaling pathway,” Metabolic Brain Disease, vol. 33, no. 6, pp. 1869–1875, 2018. View at: Publisher Site | Google Scholar
  45. X. Wu, H. Won, and D. C. Rubinsztein, “Autophagy and mammalian development,” Biochemical Society Transactions, vol. 41, no. 6, pp. 1489–1494, 2013. View at: Publisher Site | Google Scholar
  46. I. Dikic, T. Johansen, and V. Kirkin, “Selective autophagy in cancer development and therapy,” Cancer Research, vol. 70, no. 9, pp. 3431–3434, 2010. View at: Publisher Site | Google Scholar
  47. Y. Romero, M. Bueno, R. Ramirez et al., “mTORC1 activation decreases autophagy in aging and idiopathic pulmonary fibrosis and contributes to apoptosis resistance in IPF fibroblasts,” Aging cell, vol. 15, no. 6, pp. 1103–1112, 2016. View at: Publisher Site | Google Scholar
  48. A. K. Au, Y. Chen, L. du et al., “Ischemia-induced autophagy contributes to neurodegeneration in cerebellar Purkinje cells in the developing rat brain and in primary cortical neurons in vitro,” Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, vol. 1852, no. 9, pp. 1902–1911, 2015. View at: Publisher Site | Google Scholar
  49. H. Choi, C. Merceron, L. Mangiavini et al., “Hypoxia promotes noncanonical autophagy in nucleus pulposus cells independent of MTOR and HIF1A signaling,” Autophagy, vol. 12, no. 9, pp. 1631–1646, 2016. View at: Publisher Site | Google Scholar
  50. L. Ye, Z. Feng, D. Doycheva et al., “CpG-ODN exerts a neuroprotective effect via the TLR9/pAMPK signaling pathway by activation of autophagy in a neonatal HIE rat model,” Experimental Neurology, vol. 301, Part A, pp. 70–80, 2018. View at: Publisher Site | Google Scholar
  51. D. C. Rubinsztein, J. E. Gestwicki, L. O. Murphy, and D. J. Klionsky, “Potential therapeutic applications of autophagy,” Nature Reviews Drug Discovery, vol. 6, no. 4, pp. 304–312, 2007. View at: Publisher Site | Google Scholar
  52. Z. Zheng, L. Zhang, Y. Qu et al., “Mesenchymal stem cells protect against hypoxia-ischemia brain damage by enhancing autophagy through brain derived neurotrophic factor/mammalin target of rapamycin signaling pathway,” Stem Cells, vol. 36, no. 7, pp. 1109–1121, 2018. View at: Publisher Site | Google Scholar
  53. A. Melk, A. Baisantry, and R. Schmitt, “The yin and yang of autophagy in acute kidney injury,” Autophagy, vol. 12, no. 3, pp. 596-597, 2016. View at: Publisher Site | Google Scholar
  54. J. Zhou, Y. Fan, J. Zhong et al., “TAK1 mediates excessive autophagy via p38 and ERK in cisplatin-induced acute kidney injury,” Journal of Cellular and Molecular Medicine, vol. 22, no. 5, pp. 2908–2921, 2018. View at: Publisher Site | Google Scholar
  55. A. Hamacher-Brady, N. R. Brady, S. E. Logue et al., “Response to myocardial ischemia/reperfusion injury involves Bnip3 and autophagy,” Cell Death and Differentiation, vol. 14, no. 1, pp. 146–157, 2006. View at: Publisher Site | Google Scholar
  56. A. Nardin, E. Schrepfer, and E. Ziviani, “Counteracting PINK/parkin deficiency in the activation of mitophagy: a potential therapeutic intervention for Parkinson’s disease,” Current Neuropharmacology, vol. 14, no. 3, pp. 250–259, 2016. View at: Publisher Site | Google Scholar
  57. G. Amadoro, V. Corsetti, F. Florenzano et al., “Morphological and bioenergetic demands underlying the mitophagy in post-mitotic neurons: the pink–parkin pathway,” Frontiers in aging neuroscience, vol. 6, 2014. View at: Publisher Site | Google Scholar
  58. N. Dehne, T. Li, F. Petrat, U. Rauen, and H. de Groot, “Critical O2 and NO concentrations in NO-induced cell death in a rat liver sinusoidal endothelial cell line,” Biological Chemistry, vol. 385, no. 3-4, pp. 341–349, 2004. View at: Publisher Site | Google Scholar
  59. K. Zhang, J. M. Weinberg, M. A. Venkatachalam, and Z. Dong, “Glycine protection of PC-12 cells against injury by ATP-depletion,” Neurochemical Research, vol. 28, no. 6, pp. 893–901, 2003. View at: Publisher Site | Google Scholar
  60. P. Zhao, H. Qian, and Y. Xia, “GABA and glycine are protective to mature but toxic to immature rat cortical neurons under hypoxia,” The European Journal of Neuroscience, vol. 22, no. 2, pp. 289–300, 2005. View at: Publisher Site | Google Scholar
  61. F. U. Amin, S. A. Shah, and M. O. Kim, “Glycine inhibits ethanol-induced oxidative stress, neuroinflammation and apoptotic neurodegeneration in postnatal rat brain,” Neurochemistry International, vol. 96, pp. 1–12, 2016. View at: Publisher Site | Google Scholar
  62. J. van den Eynden, S. S. Ali, N. Horwood et al., “Glycine and glycine receptor signalling in non-neuronal cells,” Frontiers in Molecular Neuroscience, vol. 2, p. 9, 2009. View at: Publisher Site | Google Scholar
  63. M. Frederich and J. A. Balschi, “The relationship between AMP-activated protein kinase activity and AMP concentration in the isolated perfused rat heart,” The Journal of Biological Chemistry, vol. 277, no. 3, pp. 1928–1932, 2002. View at: Publisher Site | Google Scholar
  64. D. Qi and L. H. Young, “AMPK: energy sensor and survival mechanism in the ischemic heart,” Trends in Endocrinology and Metabolism, vol. 26, no. 8, pp. 422–429, 2015. View at: Publisher Site | Google Scholar
  65. N. Gurusamy, I. Lekli, S. Mukherjee et al., “Cardioprotection by resveratrol: a novel mechanism via autophagy involving the mTORC2 pathway,” Cardiovascular Research, vol. 86, no. 1, pp. 103–112, 2010. View at: Publisher Site | Google Scholar
  66. J. M. Rodríguez-Vargas, M. J. Ruiz-Magaña, C. Ruiz-Ruiz et al., “ROS-induced DNA damage and PARP-1 are required for optimal induction of starvation-induced autophagy,” Cell Research, vol. 22, no. 7, pp. 1181–1198, 2012. View at: Publisher Site | Google Scholar
  67. R. R. Russell III, J. Li, D. L. Coven et al., “AMP-activated protein kinase mediates ischemic glucose uptake and prevents postischemic cardiac dysfunction, apoptosis, and injury,” Journal of Clinical Investigation, vol. 114, no. 4, pp. 495–503, 2004. View at: Publisher Site | Google Scholar
  68. S. Jager, C. Handschin, J. St.-Pierre, and B. M. Spiegelman, “AMP-activated protein kinase (AMPK) action in skeletal muscle via direct phosphorylation of PGC-1α,” Proceedings of the National Academy of Sciences of the United States of America, vol. 104, no. 29, pp. 12017–12022, 2007. View at: Publisher Site | Google Scholar
  69. M. M. Mihaylova and R. J. Shaw, “The AMPK signalling pathway coordinates cell growth, autophagy and metabolism,” Nature Cell Biology, vol. 13, no. 9, pp. 1016–1023, 2011. View at: Publisher Site | Google Scholar
  70. T. A. Hopkins, J. R. B. Dyck, and G. D. Lopaschuk, “AMP-activated protein kinase regulation of fatty acid oxidation in the ischaemic heart,” Biochemical Society Transactions, vol. 31, no. 1, pp. 207–212, 2003. View at: Publisher Site | Google Scholar

Copyright © 2019 Chen-chen Cai et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

1233 Views | 291 Downloads | 0 Citations
 PDF  Download Citation  Citation
 Download other formatsMore
 Order printed copiesOrder
 Sign up for content alertsSign up

You are browsing a BETA version of Hindawi.com. Click here to switch back to the original design.